Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

H

Hvidovre University Hospital

Status

Unknown

Conditions

Overweight

Treatments

Dietary Supplement: Glucose + Canagliflozin
Dietary Supplement: Glucose

Study type

Interventional

Funder types

Other

Identifiers

NCT03426956
CM-CANA-18

Details and patient eligibility

About

To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.

Full description

Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1 transporter appears to be crucial for this response. The study will investigate the effects of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones after gastric bypass surgery.

Enrollment

10 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

•Uncomplicated gastric bypass surgery performed minimum 12 months prior to study

Exclusion criteria

  • Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery
  • Pregnancy or breastfeeding
  • Haemoglobin levels below 6,5 mM

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

10 participants in 2 patient groups

Glucose
Experimental group
Treatment:
Dietary Supplement: Glucose
Glucose + Canagliflozin
Experimental group
Treatment:
Dietary Supplement: Glucose + Canagliflozin

Trial contacts and locations

1

Loading...

Central trial contact

Sten Madsbad, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems